Skip to main navigation Skip to search Skip to main content

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13

  • Kazimierz Groen
  • , Fredrik H Schjesvold
  • , Bronno van der Holt
  • , Mark-David Levin
  • , Maarten R Seefat
  • , Markus Hansson
  • , Maria B L Leys
  • , Josien C Regelink
  • , Anders Waage
  • , Damian Szatkowski
  • , Per Axelsson
  • , Trung Hieu Do
  • , Asta Svirskaite
  • , Ellen van der Spek
  • , Einar Haukas
  • , Dorota Knut-Bojanowska
  • , Paula F Ypma
  • , Cecilie H Blimark
  • , Ulf-Henrik Mellqvist
  • , Niels W C J van de Donk
  • Pieter Sonneveld, Anja Klostergaard, Annette J Vangsted, Niels Abildgaard, Sonja Zweegman
  • Department of Hematology
  • Oslo University Hospital
  • Erasmus MC Cancer Institute
  • Albert Schweitzer Hospital
  • Lund University and Skåne University Hospital
  • Maasstad Hospital
  • 27St Olav University Hospital and Norwegian University of Science and Technology – NTNU Faculty of Medicine and Health Sciences
  • Førde Central Hospital
  • Helsingborg Hospital
  • Roskilde Sjaelland University
  • Aalborg University Hospital
  • Rijnstate Hospital
  • Stavanger University Hospital
  • Institute of Heamatology
  • Haga Hospital
  • Sahlgrenska University Hospital
  • Department of Internal Medicine
  • Aarhus University Hospital
  • Rigshospitalet
  • King Christian 10th Hospital for Rheumatic Diseases, Gråsten, and South Jutland Hospital, Denmark Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.

Research output: Contribution to journalArticleAcademicpeer-review

37 Downloads (Pure)
Original languageEnglish
Pages (from-to)e940
JournalHemaSphere
Volume7
Issue number9
DOIs
Publication statusPublished - Sept 2023

Cite this